PET for small cell lung cancer – pro
Zia et al reported that CMR on post-therapeutic FDG-PET/CT in patients with SCLC is an important prognostic factor and may help decision making for therapeutic management. Subsequent studies have echoed this conclusion. NCCN 2025 on SCL-1, 1 says: ” FDG-PET/CT scan (skull base to mid-thigh), if needed to clarify extent of disease”.
Zia D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni B, Monteil J. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria. Cancer Imaging. 2013 Mar 5;13(1):73-80. doi: 10.1102/1470-7330.2013.0008. PMID: 23466871; PMCID: PMC3589951.
Hamdan AL-Jahdali et al, Guidelines for the role of FDG-PET/CT in lung cancer management. Journal of Infection and Public Health
Volume 5, Supplement 1, December 2012, Pages S35-S40.
Martucci F, Pascale M, Valli MC, Pesce GA, Froesch P, Giovanella L, Richetti A, Treglia G. Impact of 18F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2020 Jan 29;6:336. doi: 10.3389/fmed.2019.00336. PMID: 32118000; PMCID: PMC7025551.
NCCN Smal Cell Lung Cancer 2025
Go, S. I., H. N. Song, J. H. Kang, M. H. Kang, M. J. Kim, J. Jung, S. I. Chung, B. H.
Choi, I. G. Hwang, S. H. Kim, H. Ling, and G. W. Lee. 2014. ‘The clinical impact of
the sum of the maximum standardized uptake value on the pretreatment with
FFDGPET/CT in smallcell lung cancer’, Oncology , 86: 19